Medicinal Chemistry VII Computational Chemistry, Bayer Schering Pharma AG, Berlin, Germany.
Curr Top Med Chem. 2010;10(3):346-67. doi: 10.2174/156802610790725461.
Malaria, caused by protozoa of the genus Plasmodium, remains one of the most dreadful infectious diseases worldwide killing more than 1 million people per year. The emergence of multidrug-resistant parasites highly demands a steadfast and continuous search not only for new targets but also for new anti-infectives addressing the known ones. As proteases in general have been proven to be excellent drug targets and the development of inhibitors has frequently resulted in approved drugs, this review will only focus on the proteases of Plasmodium falciparum as drug targets. The completion of the sequencing of the Plasmodium falciparum genome in 2002 lead to the discovery of nearly 100 putative proteases encoded therein. Within this review, only those proteases and inhibitors thereof will be discussed in more detail, in which their biological function has been determined undoubtedly or in those cases, in which the development of specific inhibitors has significantly contributed to the understanding of the underlying biological role of the respective protease thus validating the role as promising drug target.
疟疾是由疟原虫属原生动物引起的,仍然是全球最可怕的传染病之一,每年导致超过 100 万人死亡。多药耐药寄生虫的出现迫切需要坚定不移地持续寻找不仅是新的靶点,还有新的抗感染药物来应对已知的药物。由于蛋白酶通常被证明是优秀的药物靶点,并且抑制剂的开发经常导致批准的药物,因此本综述将仅关注疟原虫属疟原虫的蛋白酶作为药物靶点。2002 年完成了疟原虫属疟原虫基因组的测序,发现了其中编码的近 100 种假定的蛋白酶。在本综述中,仅讨论那些蛋白酶及其抑制剂,其中其生物学功能已经被确定无疑,或者在那些情况下,特定抑制剂的开发极大地促进了对各自蛋白酶的潜在生物学作用的理解,从而验证了作为有前途的药物靶点的作用。